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Abstract
Background—The Centers for Disease Control and Prevention (CDC) recommends one-time 
hepatitis C virus (HCV) antibody testing for “Birth Cohort” adults born during 1945–1965.
Objective—To examine the impact of an electronic health record (EHR)-embedded best practice 
alert (BPA) for HCV testing among Birth Cohort adults.
Design—Cluster-randomized trial was conducted from April 29, 2013 to March 29, 2014.
Subjects and Setting—Ten community and hospital-based primary care practices. Participants 
were attending physicians and medical residents during 25,620 study-eligible visits.
Intervention—Physicians in all practices received a brief introduction to the CDC testing 
recommendations. At visits for eligible patients at intervention sites, physicians received a BPA 
through the EHR to order HCV testing or medical assistants were prompted to post a testing order 
for the physician. Physicians in control sites did not receive the BPA.
Main Outcomes—HCV testing; the incidence of HCV antibody positive tests was a secondary 
outcome.
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Results—Testing rates were greater among Birth Cohort patients in intervention sites (20.2% vs. 
1.8%, P < 0.0001) and the odds of testing were greater in intervention sites after controlling for 
imbalances of patient and visit characteristics between comparison groups [odds ratio (OR), 9.0; 
95% confidence interval, 7.6–10.7). The adjusted OR of identifying HCV antibody positive 
patients was also greater in intervention sites (OR, 2.1; 95% confidence interval, 1.3–11.2).
Conclusions—An EHR-embedded BPA markedly increased HCV testing among Birth Cohort 
patients, but the majority of eligible patients did not receive testing indicating a need for more 
effective methods to promote uptake.
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BACKGROUND
In 2012, the United States Centers for Disease Control and Prevention (CDC) recommended 
one-time testing for hepatitis C virus (HCV) among individuals born during 1945–1965 (the 
baby boomer Birth Cohort), without ascertainment of risk of possible exposure to, or 
symptomatic indications of infection.1 Shortly thereafter, the United States Preventive 
Services Task Force put forth a similar guideline and effective January 1, 2014 testing baby 
boomers for HCV became public health law in New York State.2 With growing evidence to 
support birth-cohort testing3–6 and the advent of more effective HCV treatment options with 
fewer side effects,7 widespread testing has become imperative. Testing baby boomers could 
detect as many as 800,000 more cases of HCV than testing based solely on other risk factors, 
lead to treatment for up to 260,000 patients, and avert nearly 50,000 cases of hepatocellular 
carcinoma and 15,000 liver transplants.8,9
Baby boomers have been included in earlier studies of screening involving higher risk 
populations but their age group has not been specifically targeted for screening until 
recently,10,11 in a few studies limited to specialty and emergency department settings.12–14 
Moreover, some methods used to engage patients in screening place considerable demand on 
personnel resources and may not be sustainable.12–14
Electronic health records (EHR) can increase HCV testing in settings that reach large 
numbers of patients, like primary care, by alerting clinicians to current guidelines and 
facilitating test ordering.15 EHR-based alerts and interventions have improved screening 
rates for colorectal cancer and osteoporosis, uptake of appropriate vaccinations,16,17 and 
testing for other viral infections among at-risk patients18–21 in primary care settings. On the 
basis of these observations, we sought to test the impact of EHR-based alerts on HCV 
testing among members of the 1945–1965 Birth Cohort.
METHODS
Study Settings
The study took place from April 1, 2013 through March 1, 2014 in adult primary care 
practices of the Mount Sinai Healthcare System. These were academically affiliated medical 
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practices which included a hospital-based clinic and a hospital-based faculty practice, both 
located in the Upper East Side and East Harlem communities of New York City, and 
community-based faculty practices in Nassau County, Long Island, New York. The hospital 
clinic has 4 independently operating practices, employs 20 faculty physicians and is the 
outpatient training venue for 140 medical residents. It has approximately 55,000 visits each 
year. The hospital-based faculty practice consists of 12 full-time physicians who provide 
care during 35,000 patient visits annually. Mount Sinai’s North Shore (Nassau County) 
community-based faculty practice group consists of 4 practices with 12 primary care 
physicians and 3 nurse practitioners. They have approximately 62,000 visits annually. All 
practices used the Epic EHR system at the time of the study (Epic Systems, Madison, WI).
A research assistant approached all physicians, nurse practitioners, nurses, and medical 
assistants at all sites, in person or by email, described the study and requested their consent 
to receive the EHR-based alerts. The study was approved by the Institutional Review Board 
of the Icahn School of Medicine at Mount Sinai.
Study Design
The study was designed as a practice-level cluster randomized controlled trial, with clinical 
sites subdivided into 10 clusters defined by geography and functionality to decrease 
potential cross-contamination. The hospital-based clinic was divided by its 3 practice areas, 
the hospital-based faculty practice by its 2 separate practice floors, and the community-
based faculty practice by its 5 independently operating practice areas. Providers in these 
sites consistently worked in the same physical area of their practice so the risk of 
contamination across clusters was low. Randomization of clusters was performed by an 
investigator at the CDC (A.Y.) and resulted in the following study arm assignments: in the 
hospital clinic there were 2 intervention clusters and 1 control; in the hospital-based faculty 
practice there was 1 intervention cluster and 1 control; and in the community-based faculty 
practice there were 3 intervention clusters and 2 controls. Study personnel were not blinded 
to cluster assignment.
An eligible study visit was defined as a scheduled visit with a consented clinician of a Birth 
Cohort patient who had no prior HCV antibody test, hepatitis C viral load result, or prior 
diagnosis of hepatitis C as documented in the EHR.
Intervention Design and Implementation
The study intervention was a best practice alert (BPA) programmed in the EHR to appear in 
yellow highlight on the EHR-clinician interface during visits to inform clinicians of the 
patients’ eligibility for HCV testing and to facilitate testing by providing a testing order set. 
Before creating the alert, we conducted an informal focus group with attending physicians 
from the hospital-based practices to get their input on BPA design. The most consistent 
theme that emerged was efficiency, as exemplified by suggestions for prepopulated 
laboratory orders, minimal navigation through the chart (ie, few clicks of the mouse), and 
minimal disruption to work flow. These recommendations were integrated into the design of 
the BPA. The BPA was pilot tested with staff at each site and adjustments were made to 
ensure fit with local workflow.
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The intervention consisted of 2 pathways. Pathway 1: if a medical assistant opened the chart 
for an eligible patient before the clinician did (eg, to enter the patient’s vital signs data), he 
or she would encounter a BPA prompting them to order an HCV test. The order would 
appear as “pended” when the clinician opened the chart, at which time the clinician could 
choose to discuss testing with the patient, sign the order, or delete it. This pathway required 
just 1 click of the mouse by the clinician.
Pathway 2: if the clinician opened the chart before the medical assistant or if the medical 
assistant bypassed the alert presented through pathway 1, a different BPA appeared for the 
clinician. This BPA briefly outlined the Birth Cohort testing guidelines and suggested HCV 
testing for the patient. The alert also presented an order, known as a “smart set,” for HCV 
testing which the clinician could accept or bypass. The HCV testing BPAs for both pathways 
would continue to appear at subsequent visits until an HCV testing order was placed. An 
order pended by the medical assistant could not be placed unless the clinician ultimately 
signing the order associated it with the appropriate diagnosis (also pended through the BPA). 
This step ensured that no HCV tests were ordered inadvertently. Furthermore, the clinician 
could delete the pended test based on their clinical judgment in the same manner that any 
order in the EHR could be removed. The BPA would reappear at subsequent visits until 
HCV testing was ordered or the clinician selected the option to delay or permanently 
exclude the patient from testing. Data on the reasons why physicians chose to exclude 
patients from testing were not included.
The clinical staff members of all practices were blinded to study assignment and all 
underwent the same standardized education about HCV infection, Birth Cohort testing 
recommendations, and HCV treatment referral resources within the Mount Sinai Healthcare 
System.
A research assistant on the study team was assigned to contact physicians if patients who 
tested positive for HCV antibody did not receive a confirmatory hepatitis C viral load test 
within 90 days of the positive test. This was not a feature of the intervention design.
Measures
The primary outcome was the rate of HCV antibody testing during eligible study visits in the 
intervention and control practices. HCV antibody testing was identified through automated 
reports from the EHR. The secondary outcome was HCV antibody positivity rates among 
tested individuals. Explanatory variables were also identified through the EHR and included 
patient sociodemographic and health status characteristics (age, sex, race and ethnicity, 
insurance type, quartile of median income from zip code data matched to census blocks, and 
comorbidities). Age was categorized for ease of interpretation. Clinicians were characterized 
as attending physicians or medical residents using administrative data.
We hypothesized that HCV testing would be less likely to occur during complex encounters 
or encounters that required more work of the clinician. To represent encounter complexity, 
we used level of service and number of diagnosis codes [International Classification of 
Diseases, Ninth Revision (ICD-9)] listed for the encounter. To represent provider workload, 
we measured counts of active BPAs for actions other than HCV testing and the number of 
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orders placed during visits. The blood tests excluded orders placed for HCV antibody or 
viral load testing. Further, we separated blood testing from orders for other services (other 
testing, medications or supplies, procedures, referrals) on the assumption that clinicians 
might be more inclined to order HCV tests if they were already ordering blood work.
Statistical Analysis
The main outcomes were HCV testing and HCV antibody positivity. Visits were the unit of 
analysis. Subsequent visits in which the patient was tested for HCV were censored because 
the CDC recommendations call for one-time testing only. We used generalized estimating 
equations (GEE) to model the outcomes as well as to test differences in characteristics of 
visits between intervention and control sites. We chose GEE to account for the potential 
correlations arising from repeated visits by individual patients and clustering of patients by 
physician. All models used a binomial distribution, logit link function, and a robust 
covariance matrix. The models included the proxy measures of visit complexity and 
workload intensity and were adjusted for patient and site characteristics that differed 
significantly between the intervention and control sites (P < 0.05). We estimated a minimum 
sample size of 440 visits per cluster to detect an absolute difference in testing between 
intervention and control sites of 2.5% (eg, 8.5% vs. 6.0%)14 with a type I error of 5%, power 
of 80%, and intracluster correlation coefficient of 0.005.22
In a set of exploratory analyses, we separately modeled HCV antibody testing in 
intervention and control sites to identify the practice and visit-level factors associated with 
testing in those settings. Statistical analyses were performed using the GENMOD procedure 
in SAS (version 9.4; SAS Institute Inc., Cary, NC).
RESULTS
Study Enrollment
Study enrollment is shown in Figure 1. In the intervention sites, 26 clinicians did not attend 
one or any of the HCV education sessions required for study participation or attended but 
left before the session was completed. In the control sites, 11 clinicians did not attend or 
remain until the end of the session. In addition, 4 clinicians who attended the entire 
educational session at control sites refused to provide written consent for study participation. 
They provided no reason for their refusal. Data on visits made to 82 clinicians in the 
intervention arm and 45 in the control arm were used in the final analyses.
Visit and Setting Characteristics
Across the 10 sites, 14,151 study-eligible patients made 25,821 visits between April 29, 
2013 and March 29, 2014 (intervention arm, n = 15,010; control arm, n = 10,811). We 
censored 201 visits. The final sample consisted of 25,620 visits, with 14,825 visits to the 
intervention sites and 10,795 visits to the control sites. The number of unique individuals 
seen during these visits was 8713 in the intervention sites and 5438 in the control sites. The 
majority of visits were made by patients who were female (61.8%), white non-Hispanic 
(75.0%), and privately insured (76.1%) and most occurred in community-based practice 
settings (70.4%) (Table 1).
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Visit characteristics differed between intervention and control sites for all variables except 
patient age and proportion of resident physicians. Notably, visits at intervention sites 
included fewer white, non-Hispanic patients (71.6% vs. 79.7%, P < 0.0001), fewer publicly 
insured or uninsured patients (75.2% vs. 77.2%, P < 0.0001), and fewer attending hospital-
based practices (65.4% vs. 77.3%, P < 0.0001) (Table 1).
HCV Antibody Testing
Testing occurred 18.4% more frequently at visits in intervention sites (2995/14,825 patient-
eligible visits, 20.2%) compared with control sites (198/10,795 visits, 1.8%) (P < 0.0001). 
After adjustment for visit-level characteristics, the odds ratio (OR) for testing at intervention 
versus control sites was 9.0, 95% confidence interval (CI), 7.6–10.7; P < 0.0001 (Table 2). 
The intraclass correlation coefficient for the clustering effect was 0.173. HCV testing was 
more likely to be ordered when more blood tests or other types of orders were placed and 
when visit complexity was coded as high. Visits involving nonwhite, publicly insured 
patients residing in the zip code areas with median incomes between $65,000 and $92,999, 
and those with visits occurring outside of faculty practice settings were significantly less 
likely to involve HCV testing.
Identification of HCV Antibody-positive Cases
The number of HCV antibody-positive patients identified at visits for Birth Cohort patients 
was greater in intervention than in control sites [27 HCV antibody-positive cases among 
8713 unique patients (3.1%) in the intervention arm vs. 6 cases among 5438 unique patients 
(1.1%) in the control arm; P < 0.0001). Overall, the OR for identifying an HCV antibody-
positive Birth Cohort patient was 2.1 (95% CI, 1.33–11.2; P = 0.01) compared with control 
sites, adjusting for sex, race, and insurance status.
Patient and Visit Characteristics Associated With HCV Testing Within Intervention and 
Control Sites
Within intervention sites, testing was more likely at visits involving male patients (OR, 1.22; 
95% CI, 1.09–1.35) and patients residing in zip codes with lower median incomes (Table 3). 
It was also more likely to occur during visits in which multiple blood or nonblood tests were 
ordered (blood tests: ≥5 vs. 0; OR, 10.9; 95% CI, 9.10–13.2 and nonblood tests: ≥4 vs. 0; 
OR, 3.28; 95% CI, 2.72–3.96), and the level of service was of high complexity and/or 
involved a new patient. Testing was less likely to occur during visits made by black patients 
(OR, 0.80; 95% CI, 0.67–0.96) and non-Hispanic patients of other races (OR, 0.81; 95% CI, 
0.67–0.99) compared with visits by white patients, visits by patients with public versus 
private insurance, and visits to hospital clinics and community-based practices compared 
with hospital-based faculty practices.
In sites without the EHR-based HCV testing BPAs, testing was less likely for men, visits 
with ≤3 EHR alerts, where ≥5 blood tests were ordered, or the visit was billed as other than 
established patient/low-moderate complexity (control sites, Table 3). Testing was less likely 
for patients ages 65 years and older, black or Hispanic, Medicaid covered or uninsured, or 
who received their care in a community-based faculty practice.
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DISCUSSION
In this cluster-randomized trial, prompting physicians to test Birth Cohort patients with 
alerts that appeared in the EHR resulted in a 9-fold higher rate of testing compared with that 
of patients in sites where no BPA was provided. Moreover, more patients with HCV 
antibodies were identified in the intervention sites compared with the control sites.
To date, no randomized controlled trials of HCV testing have been conducted in primary 
care settings, whether targeting Birth Cohort patients or others. Before this work, 
observational studies suggested that EHR-directed testing was a promising strategy even 
though these studies could not fully determine the impact of EHR-based testing.4,23–25 
White et al23 reported the results of HCV testing in an emergency department in which a 
triage nurse offered HCV testing to patients with history of injection drug use or who were 
born between 1945 and 1964 when prompted by an EHR-based alert. Approximately half of 
age-eligible patients were offered HCV testing and 29% of them received testing, among 
whom 11% were positive. In another emergency department study that followed a similar 
protocol, 87% of eligible patients accepted testing and 11% of tested subjects were HCV 
antibody-positive.12 Notably, testing rates in these 2 studies were higher than what we 
observed in our study. Clinicians may be more likely to test for HCV in settings like 
emergency departments where more people are likely to have undiagnosed HCV infection 
than in general primary care.26
Testing has also been evaluated in primary care and in-patient settings. Litwin and 
colleagues used a multi-component intervention to promote testing among at-risk patients in 
primary care, including Birth Cohort patients, that involved physician-targeted HCV 
education supported by regular follow-up communication about the testing process, visual 
reminders to prompt testing (buttons, posters, and pocket cards), and flagging charts of 
qualified patients. This approach increased testing from 6.0% to 9.9%.14 Turner et al24 
tested hospital in-patients identified by the EHR using an opt-out approach. Orders were 
automatically placed in most cases, although one third of orders had to be manually entered 
by a clinician. Testing was performed on 49% of eligible patients, among whom 7.6% were 
positive.
Taken together, these observational studies demonstrate that EHR-embedded BPAs can 
boost HCV testing in varied clinical settings. Our study moves beyond this work by 
comparing brief physician education combined with EHR-embedded BPAs for HCV testing 
to physician education alone in primary care in a large scale, cluster-randomized trial. This 
approach enables a direct assessment of the impact of this testing modality, and clearly 
demonstrates the benefit of the BPA.
Despite the success of the intervention, the overall rate of testing using EHR prompts was 
low: only one fifth of eligible patients were tested. This finding is consistent with literature 
on clinical decision support, which shows that clinical decision support in various settings, 
including primary care, often has only a moderate impact on physician action,27,28 
preventive care testing rates,29–31 adherence to treatment guidelines,32,33 and meeting 
quality of care standards.34 A number of factors may be at play, including the physicians’ 
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workload, perceived inapplicability of the recommendations, inadequate time to document 
why recommendations were not followed, a lack of training to prepare or prime the end-
users, and distraction from the doctor-patient interaction by the electronic reminder.35,36 
Similar barriers have been reported elsewhere.30,37
Given that workload limits physicians’ responses to electronic reminders, we were surprised 
to find that testing occurred more often during visits of greater complexity, as indicated by 
more diagnoses, more orders placed (blood work and others), or higher level of service 
codes. As the automated reminder prepopulated the order set, signing off on it may have 
been easier for physicians if they already had other orders present. Alternatively, physicians 
may have been more inclined to test individuals who had greater morbidity. However, these 
considerations are speculative.
We also identified disparities in testing, with lower rates of HCV testing among black 
patients and those with Medicaid coverage in both the intervention and control sites, 
consistent with observations elsewhere.38 However, disparities were less pronounced in 
intervention sites suggesting that automated prompts for testing may reduce them. 
Examining physicians’ and patients’ experiences with the BPA testing procedure was 
beyond the scope of this project and the data collected did not enable us to determine 
whether disparities were the result of physician practice or patient preference, or both. 
Regardless, more research is needed to understand patterns of test ordering and to ultimately 
improve on the suboptimal rate of testing produced by this intervention.
Although there was variation in the type of clinical primary care practices involved in this 
study, our study is limited in generalizability by the exclusive participation of practices from 
a single health care system. In addition, covariate balance between intervention and control 
sites was not fully achieved, although we controlled for imbalances between these groups 
using multivariable GEE. Clinicians who did not attend the educational sessions on the CDC 
Birth Cohort testing recommendations were not consented to participate in the study and 
data from their patient encounters were not included in our analyses. Whether there was a 
general bias in favor or against Birth Cohort testing among these clinicians is unknown.
Testing high-prevalence cohorts for HCV is an increasingly important service that primary 
care providers can offer. This study demonstrates that EHR-based reminders can increase 
HCV antibody testing among Birth Cohort patients. Nonetheless, overall testing rates were 
low, suggesting that this strategy needs more study, including a better understanding of the 
role of physician beliefs and knowledge about Birth Cohort testing, to improve its efficacy. 
Still, EHR-based reminders should perhaps be coupled with other strategies to achieve 
widespread testing of Birth Cohort patients.
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FIGURE 1. 
Study enrollment. HCV indicates hepatitis C virus.
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TABLE 1
Patient, Setting, and Service Characteristics, by Study Arm
Study Arm (%)
All Visits (N = 
25,620) (%)
Intervention (N = 14,825) Control (N = 10,795) P
Patient age (y) 0.94
 49–54 29.2 29.2 29.2
 55–64 47.8 48.0 47.7
 ≥65 23.0 22.8 23.1
Patient sex, male 38.2 36.7 40.3 0.0005
Patient race < 0.0001
 White, non-Hispanic 75.0 71.6 79.7
 Black, non-Hispanic 9.6 11.9 6.4
 Hispanic 9.3 10.0 8.4
 Other 6.2 6.6 5.6
Median income by zip code < 0.0001
 ≥$108,000 27.5 25.4 30.3
 $93,000–$107,999 26.4 22.3 32.0
 $65,000–$92,999 25.3 28.3 21.1
 < $65,000 20.9 24.1 16.6
Patient insurance < 0.0001
 Private 76.1 75.2 77.2
 Medicare 18.5 18.2 18.8
 Medicaid/uninsured 5.5 6.5 4.0
Practice setting < 0.0001
 Hospital-based faculty practice 17.1 18.6 15.1
 Hospital-based clinic 12.4 16.0 7.6
 Community-based faculty practice 70.4 65.4 77.3
Physician level* 0.06
 Attending 94.3 94.1 94.7
 Resident 5.7 6.0 5.3
# EHR alerts presented to physician during visit < 0.0001
 1–2 7.8 6.0 10.4
 3–5 67.0 63.8 71.3
 ≥6 25.2 30.3 18.3
# Diagnosis codes listed for the visit < 0.0001
 0–2 17.1 23.0 9.1
 3–5 32.2 30.7 34.2
 6–8 22.5 20.4 25.3
 ≥9 28.2 25.9 31.4
# Blood tests ordered during visit† < 0.0001
 0 82.1 76.1 90.3
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Study Arm (%)
All Visits (N = 
25,620) (%)
Intervention (N = 14,825) Control (N = 10,795) P
 1–4 9.7 12.6 5.7
 ≥5 8.2 11.3 4.0
# Orders other than blood tests placed during visit‡ < 0.0001
 0 22.4 21.1 24.1
 1–3 59.5 51.8 69.9
 ≥4 18.2 27.1 6.0
Level of service coded for visit 0.003
 Established patient/low-moderate complexity 72.5 72.6 72.3
 Established patient/high complexity 20.5 19.8 21.3
 New patient/low-moderate complexity 5.2 5.7 4.6
 New patient/high complexity 1.8 1.9 1.7
Some values in columns do not sum to 100% owing to rounding error.
*Among sites that included residency training. Total numbers of patients at control sites, n = 509; intervention sites, n = 1498.
†
Excludes hepatitis C virus antibody and RNA testing.
‡Orders for referrals, procedures, medications, supplies, and any testing except blood testing.
EHR indicates electronic health record.
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TABLE 2
Adjusted ORs for Hepatitis C Virus Antibody Testing During Visits for Screening-eligible Birth Cohort 
Members in Intervention Versus Control Sites (n = 25,620)
OR (95% CI) P
Study arm
 Control Ref.
 Intervention 8.99 (7.57–10.7) < 0.0001
Age (y)
 49–54 Ref.
 55–64 0.96 (0.85–1.07) 0.46
 ≥65 0.98 (0.84–1.14) 0.76
Patient sex, male 1.27 (1.15–1.41) < 0.0001
Race
 White, non-Hispanic Ref.
 Black, non-Hispanic 0.76 (0.64–0.91) 0.002
 Hispanic 0.81 (0.67–0.97) 0.02
 Other 0.79 (0.66–0.96) 0.02
Median income by zip code
 ≥$108,000 Ref.
 $93,000–$107,999 1.20 (1.02–1.41) 0.02
 $65,000–$92,999 1.54 (1.33–1.79) < 0.0001
 < $65,000 1.06 (0.89–1.26) 0.54
Insurance
 Private Ref.
 Medicare 0.65 (0.56–0.76) < 0.0001
 Medicaid/uninsured 0.53 (0.42–0.66) < 0.0001
Practice setting
 Hospital-faculty practice Ref.
 Hospital-clinic 0.51 (0.43–0.61) < 0.0001
 Community-faculty practice 0.06 (0.05–0.07) < 0.0001
# EHR alerts presented to the physician
 1–2 Ref.
 3–5 1.36 (1.12–1.66) 0.002
 ≥6 1.12 (0.91–1.39) 0.29
# Diagnosis codes listed for the visit
 0–2 Ref.
 3–5 1.10 (0.96–1.26) 0.19
 6–8 1.01 (0.87–1.8) 0.90
 ≥9 1.00 (0.86–1.17) 0.97
# Blood tests ordered during visit*
 0 Ref.
 1–4 5.01 (4.19–5.99) < 0.0001
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OR (95% CI) P
 ≥5 11.2 (9.42–13.3) < 0.0001
# Orders other than blood tests placed during visit† Ref.
 0 1.77 (1.54–2.04)
 1–3 3.39 (2.87–4.00) < 0.0001
 ≥4 < 0.0001
Level of service coded for visit
 Established/low-moderate complexity Ref.
 Established/high complexity 1.45 (1.28–1.65) < 0.0001
 New/low-moderate complexity 1.98 (1.62–2.41) < 0.0001
 New/high complexity 1.81 (1.33–2.46) 0.0001
*
Excludes hepatitis C virus antibody and RNA testing.
†Orders for referrals, procedures, medications, supplies, and any testing except blood testing.
CI indicates confidence interval; EHR, electronic health record; OR, odds ratios; Ref., reference.
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TABLE 3
Adjusted ORs for Hepatitis C Virus Antibody During Visits for Screening-eligible Birth Cohort Members, 
Stratified by Intervention (n = 14,825) and Control Sites (n = 10,795)
Hepatitis C Virus Testing
Characteristics Intervention Sites OR (95% CI) P Control Sites OR (95% CI) P
Patient age (y)
 49–54 Ref. Ref.
 55–64 1.00 (0.86–1.09) 0.58 0.87 (0.60–1.26) 0.45
 ≥65 1.04 (0.88–1.22) 0.67 0.49 (0.29–0.83) 0.008
Patient sex, male 1.22 (1.09–1.35) 0.0004 1.84 (1.31–2.58) 0.0005
Patient race/ethnicity
 White, non-Hispanic Ref. Ref.
 Black, non-Hispanic 0.80 (0.67–0.96) 0.02 0.53 (0.31–0.92) 0.02
 Hispanic 0.88 (0.73–1.07) 0.21 0.51 (0.31–0.84) 0.009
 Other 0.81 (0.67–0.99) 0.04 0.69 (0.39–1.22) 0.20
Median income by zip code
 ≥$108,000 Ref. Ref.
 $93,000–$107,999 1.24 (1.05–1.47) 0.01 0.92 (0.55–1.55) 0.77
 $65,000–$92,999 1.65 (1.41–1.92) < 0.0001 0.59 (0.34–1.03) 0.06
 < $65,000 1.12 (0.93–1.34) 0.23 0.60 (0.36–1.00) 0.05
Patient insurance
 Private Ref. Ref.
 Medicare 0.64 (0.54–0.75) < 0.0001 0.82 (0.51–1.31) 0.41
 Medicaid/uninsured 0.59 (0.47–0.75) < 0.0001 0.04 (0.01–0.32) 0.002
Practice setting
 Hospital-based faculty practice Ref. Ref.
 Hospital-based clinic 0.47 (0.39–0.56) < 0.0001 1.23 (0.77–1.96) 0.38
 Community-based faculty practice 0.07 (0.05–0.08) < 0.0001 0.01 (0.01–0.05) < 0.0001
# EHR alerts presented to the physician
 1–2 Ref. Ref.
 3–5 1.29 (1.03–1.60) 0.02 1.84 (1.10–3.08) 0.02
 ≥6 1.05 (0.83–1.32) 0.71 1.81 (1.03–3.17) 0.04
# Diagnosis codes listed for the visit
 0–2 Ref. Ref.
 3–5 1.10 (0.95–1.26) 0.20 1.39 (0.69–2.81) 0.36
 6–8 0.97 (0.83–1.14) 0.73 1.86 (0.92–3.76) 0.08
 ≥9 0.98 (0.83–1.15) 0.78 1.48 (0.75–2.93) 0.26
# Blood tests ordered during the visit*
 0 Ref. Ref.
 1–4 4.94 (4.08–5.97) < 0.0001 1.81 (0.50–6.59) 0.38
 ≥5 10.9 (9.10–13.2) < 0.0001 6.89 (1.82–26.14) 0.005
# Orders other than blood tests placed during visit†
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Hepatitis C Virus Testing
Characteristics Intervention Sites OR (95% CI) P Control Sites OR (95% CI) P
 0 Ref. Ref.
 1–3 1.68 (1.44–1.97) < 0.0001 1.18 (0.71–1.96) 0.52
 ≥4 3.28 (2.72–3.96) < 0.0001 0.99 (0.43–2.28) 0.98
Level of service coded for visit
 Established patient/low-moderate  complexity Ref. Ref.
 Established patient/high complexity 1.48 (1.29–1.69) < 0.0001 1.67 (1.09–2.55) 0.02
 New patient/low-moderate complexity 1.87 (1.53–2.30) < 0.0001 3.54 (2.02–6.18) < 0.0001
 New patient/high complexity 1.75 (1.25–2.44) 0.001 2.16 (1.03–4.53) 0.04
*
Excludes hepatitis C virus antibody and RNA testing.
†Orders for referrals, procedures, medications, supplies, and any testing except blood testing.
CI indicates confidence interval; EHR, electronic health record; OR, odds ratios; Ref., reference.
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